Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Fiche publication
Date publication
avril 2021
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Dr DESMOULINS Isabelle, Dr JOUANNAUD Christelle
Tous les auteurs :
Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Diéras V, Dalenc F, Gonçalves A, Debled M, Patsouris A, Mouret-Reynier MA, Mailliez A, Clatot F, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Lacroix-Triki M, Deluche E, Robain M, Courtinard C, Bachelot T, Brain E, Pérol D, Delaloge S
Lien Pubmed
Résumé
Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit of new treatments. ESME (Epidemio-Strategy-Medico-Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data of all consecutive MBC patients who initiated their treatment in 18 French Cancer Centres since 2008.
Mots clés
HER2, metastatic breast cancer, new drugs, overall survival, real-life
Référence
ESMO Open. 2021 Apr 22;6(3):100114